NICE amends depression and anxiety guidance
25 April 2007
Guidance on the management of depression and anxiety in primary and secondary care has been amended by the National Institute of Health and Clinical Excellence (NICE).
Depression and anxiety guidance amended
The guidance, originally published in December 2004, has been updated following safety advice issued by the MHRA on the prescription of venlafaxine.
The main changes to the anxiety guideline are on the use of pharmacological therapy and the considerations that need to be made before prescribing venlafaxine if appropriate. The main changes to the depression guideline are on the use of antidepressants especially in patients with cardiovascular disease and the special considerations that need to be taken into account when switching treatment to venlafaxine.
Mercia Page, NICE clinical practice centre director, said: 'Both anxiety and depression are common conditions which can have a significant impact on a person's quality of life. It is important that we amend our guidance to ensure that each guideline remains relevant and useful to healthcare professionals, patients and carers.'
The guidance in available on the NICE website.
Additional Information

Latest jobs Jobs web feed
- 2X Part Time Salaried GPs Deerness Park Medical Centre Competitive, Sunderland Tyne & Wear
- Full time GP partner - Isle of Man Laxey and Village Walk Health Centres Competitive, Isle of Man
- General Practitioner x 2 for MOD, RAF Leuchars, Fife MMP Competitive hourly rates offered, East Coast of Scotland
- Locum GPs Urgently Required OOH's Earn up to £70 per hour!! Merco £70/hour, South East region
- GP Locum in Greater Manchester - Long Term Locum Fresh Medical Recruitment £75 per hour, Greater Manchester
- Opportunity to be Working as a Locum GP in Surrey, Sussex and Kent with Capital Locums whenever you want from £72 Capital Group Locums From £72ph, Surrey, Sussex and Kent
Most read
Most commented
MIMS Drug Search
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.









